Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC)

被引：0

作者：

Domingo, J. Serrano ^{[1
]}

Huertas, R. Martin ^{[1
]}

Garcia, A. Barquin ^{[1
]}

de la Fuente, E. Corral ^{[1
]}

Serrano, C. Saavedra ^{[1
]}

Delgado, M. Villamayor ^{[2
]}

Saez, O. Martinez ^{[2
]}

Munoz, F. Longo ^{[3
]}

Olmos, V. Pachon ^{[2
]}

Garrote, M. Rodriguez ^{[2
]}

Vaz, M. ^{[3
]}

Puertas, P. Reguera ^{[2
]}

Fuentes, R. ^{[1
]}

Carrato, A. ^{[4
]}

Monteagudo, R. Ferreiro ^{[2
]}

机构：

[1] Ramon & Cajal Hosp, Madrid, Spain

[2] Ramon & Cajal Univ Hosp, Madrid, Spain

[3] Hosp Univ Ramon & Cajal, Madrid, Spain

[4] Alcala Univ, Hosp Univ Ramon & Cajal, CIBERONC, IRYCIS, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P - 238

引用

页数：1

共 50 条

[41] Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute
Lin, Chun-Chi
Lin, Jen-Kou
Chang, Shih-Ching
Wang, Huann-Sheng
Yang, Shung-Haur
Jiang, Jeng-Kai
Chen, Wei-Shone
Lin, Tzu-Chen
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (06) : 665 - 676
[42] Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute
Chun-Chi Lin
Jen-Kou Lin
Shih-Ching Chang
Huann-Sheng Wang
Shung-Haur Yang
Jeng-Kai Jiang
Wei-Shone Chen
Tzu-Chen Lin
International Journal of Colorectal Disease, 2009, 24 : 665 - 676
[43] The management of brain disease (BD) in ALK-rearranged non-small cell lung cancer (ALK NSCLC): Can systemic treatment delay the initiation of local treatments? Experience of the Ramon y Cajal University Hospital (RyCUH, Madrid)
Martin Huertas, R.
Ciscar Garcia, I.
Saavedra Serrano, C.
Serrano Domingo, J. J.
Corral de la Fuente, E.
Soto Castillo, J. J.
Gomez Rueda, A.
Olmedo Garcia, M. E.
Garrido Lopez, P.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S125 - S125
[44] Pilot study of the combination of capecitabine plus oxaliplatin as adjuvant therapy for patients with stage III and high risk stage II colon cancer
Olier, C.
Reyna, C.
Aramendia, J. M.
Rodriguez, J.
Viudez, A.
Chopitea, A.
Garcia-Foncillas, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[45] Factors associated with delayed time to adjuvant chemotherapy (AC) in stage III colon cancer: British Columbia Cancer Agency (BCCA) cohort experience
Chan, A.
Woods, R.
Gill, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[46] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
Moretto, Roberto
Falcone, Alfredo
Cremolini, Chiara
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
[47] Combining pathological risk factors and T, N staging to optimize the assessment for risk stratification and prognostication in low-risk stage III colon cancer
Zhen-Yu Xian
Yi-Wen Song
Zong-Jin Zhang
Ying-Guo Gan
Yong-Le Chen
Tuo Hu
Xiao-Feng Wen
Tai-Wei Mo
Xiao-Wen He
World Journal of Surgical Oncology, 22
[48] Combining pathological risk factors and T, N staging to optimize the assessment for risk stratification and prognostication in low-risk stage III colon cancer
Xian, Zhen-Yu
Song, Yi-Wen
Zhang, Zong-Jin
Gan, Ying-Guo
Chen, Yong-Le
Hu, Tuo
Wen, Xiao-Feng
Mo, Tai-Wei
He, Xiao-Wen
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
[49] High-risk clinical and pathologic features define prognostic subsets among stage III colon cancer patients
Rosales Sotomayor, A.
Rosas, V.
Noguez Ramos, A.
Gamboa Dominguez, A.
Huitzil Melendez, F. D.
Mora-Pineda, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S349 - S349
[50] Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer
Verhoeff, S. R.
van Erning, F. N.
Lemmens, V. E. P. P.
de Wilt, J. H. W.
Pruijt, J. F. M.
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 187 - 193

← 1 2 3 4 5 →